List of Excipients in Branded Drug CEFUROXIME AXETIL FOR ORAL SUSPENSION

Generic Drugs Containing CEFUROXIME AXETIL FOR ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
Ranbaxy Pharmaceuticals Inc	cefuroxime axetil	63304-963	ASPARTAME
Ranbaxy Pharmaceuticals Inc	cefuroxime axetil	63304-963	HYPROMELLOSE PHTHALATE
Ranbaxy Pharmaceuticals Inc	cefuroxime axetil	63304-963	MANNITOL
Ranbaxy Pharmaceuticals Inc	cefuroxime axetil	63304-963	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

What are the Most Frequently-Used Excipients in CEFUROXIME AXETIL FOR ORAL SUSPENSION?

# Of NDCs	Excipient
1	ASPARTAME
1	HYPROMELLOSE PHTHALATE
1	MANNITOL
1	METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER

Cefuroxime Axetil for Oral Suspension: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 3, 2026

Cefuroxime axetil for oral suspension is an off-patent, pediatric-oriented oral antibiotic with commercial potential in taste-masked generics, flexible reconstitution systems, and markets where liquid dosage forms remain important. The principal technical barriers are poor aqueous solubility, unpleasant taste, hydrolysis risk after reconstitution, dose uniformity, and the need to maintain acceptable antibiotic exposure relative to tablets. The strongest opportunities are formulation execution and supply reliability rather than new-molecule exclusivity.

What is cefuroxime axetil for oral suspension?

Cefuroxime axetil is the orally absorbed prodrug of cefuroxime, a second-generation cephalosporin. Oral suspension products are supplied as dry powders and reconstituted before dispensing. Common strengths are 125 mg/5 mL and 250 mg/5 mL, expressed as cefuroxime equivalents.[1]

The formulation is used primarily when pediatric or swallowing-impaired patients cannot take tablets. The product label instructs administration with food because food improves cefuroxime axetil absorption. The suspension has lower systemic exposure than tablets at comparable nominal doses, making formulation performance and labeling consistency commercially important.[1]

Attribute	Typical product characteristic
Active ingredient	Cefuroxime axetil
Active moiety	Cefuroxime
Dosage form	Powder for oral suspension
Common strengths	125 mg/5 mL and 250 mg/5 mL
Route	Oral
Primary users	Pediatric patients and patients unable to swallow tablets
Reconstitution	Water added before dispensing
Storage after reconstitution	Refrigerated storage is generally required
In-use period	Commonly 10 days under the reference labeling
Administration	With food
Regulatory pathway	Abbreviated New Drug Application for qualifying generics
Patent status	Core composition and early formulation rights are expired

What excipients are used in cefuroxime axetil oral suspension?

The reference formulation uses a multifunctional excipient system rather than a single taste-masking agent. Public labeling identifies excipients including sucrose, xanthan gum, hypromellose, povidone, colloidal silicon dioxide, stearic acid, acesulfame potassium, and fruit flavoring. Aspartame may also be present in specific reference or generic formulations and creates a phenylalanine-labeling requirement.[1,2]

What does each excipient do?

Excipient class	Commercial and technical function
Sucrose	Bulking agent, sweetness, mouthfeel, and suspension density adjustment
Xanthan gum	Suspending agent and viscosity modifier
Hypromellose	Viscosity control, particle wetting, and physical stabilization
Povidone	Binder or dispersibility aid
Colloidal silicon dioxide	Powder flow, moisture control, and anti-caking support
Stearic acid	Hydrophobic surface modification and manufacturing aid
Acesulfame potassium	High-intensity sweetness
Aspartame	Sweetness and taste correction where used
Fruit flavor	Reduction of residual cephalosporin bitterness
Purified water	Reconstitution vehicle

The target is not maximum viscosity. Excessive viscosity can impair pouring, dosing accuracy, redispersion, and patient acceptability. A commercially robust formula must remain pourable after refrigeration and redisperse with ordinary shaking.

Which excipient problems control product performance?

How should cefuroxime axetil taste be masked?

Cefuroxime axetil has a bitter and persistent taste. Sweeteners alone are usually insufficient. A practical strategy combines:

1. Particle-size control or coated drug particles.
2. A high-intensity sweetener system.
3. Fruit flavor selected for aftertaste suppression.
4. Viscosity control that limits immediate drug contact with taste receptors.
5. Packaging that supports rapid administration after shaking.

Ion-exchange resins, lipid coatings, polymer coatings, cyclodextrins, and complexation systems may improve taste, but each can affect drug release, bioavailability, powder flow, and regulatory comparability. For an ANDA, the lowest-risk route is usually a conventional suspension with well-controlled particle size and an excipient system close to established products.

How should the formulation address cefuroxime axetil stability?

The dry powder is materially more stable than the reconstituted suspension. Water activates hydrolytic degradation pathways and creates a limited in-use period. The formulation must control:

• Residual moisture in the powder.
• Water activity after reconstitution.
• pH drift.
• Sedimentation and caking.
• Microbial growth.
• Container-closure moisture ingress.
• Degradation during refrigerated storage.

The label’s refrigeration requirement creates a supply-chain burden. A formulation that maintains acceptable potency and microbiological quality at controlled room temperature could have commercial value, particularly in emerging markets and outpatient settings with unreliable cold-chain access. Such a claim would require substantial stability and regulatory support.

Is a preservative necessary?

Preservative selection is a trade-off. A preservative can improve microbial robustness after reconstitution, but it may create pediatric safety, taste, compatibility, or regulatory issues. The manufacturer must demonstrate antimicrobial effectiveness under the applicable pharmacopoeial standard and validate the product through the full labeled in-use period.

A preservative-free product can be commercially attractive for pediatric use, but it requires strong control of water quality, manufacturing hygiene, container design, reconstitution instructions, and stability. The business case depends on whether the target market rewards the claim sufficiently to offset development and validation costs.

What formulations are protected by cefuroxime axetil patents?

The original cefuroxime axetil composition patents are expired. A historical patent associated with cefuroxime axetil is U.S. Patent No. 4,562,181, covering cefuroxime axetil chemistry and related pharmaceutical use concepts.[3] Its term ended years ago under the applicable historical patent-term rules.

The remaining intellectual-property opportunity is more likely to involve narrow formulation or manufacturing claims, including:

• Taste-masked cefuroxime axetil particles.
• Controlled particle-size distributions.
• Moisture-protective dry powder blends.
• Improved reconstitution systems.
• Room-temperature-stable suspensions.
• Specific coating polymers.
• High-load pediatric dosage forms.
• Manufacturing processes that improve flow and dose uniformity.
• Alternative container-closure systems.

A later patent can create freedom-to-operate risk even when the active ingredient is public domain. The practical question is whether a proposed formulation practices an unexpired claim in the target jurisdiction. Generic developers should assess U.S., European, Indian, Brazilian, Chinese, and other national patent registers separately because formulation patents and enforcement positions vary by country.

What is the Orange Book status of cefuroxime axetil oral suspension?

Cefuroxime axetil is a small-molecule antibiotic, not a biologic. It therefore does not face biosimilar regulation. Generic competition proceeds through the ANDA pathway when an approved reference listed drug is available and the applicant can demonstrate pharmaceutical equivalence, bioequivalence, and quality compliance.[4]

The relevant Orange Book issues are:

Regulatory issue	Commercial implication
Reference listed drug status	Determines whether an ANDA can rely on the reference product
Listed patents	Determines Paragraph IV or Paragraph III certification strategy
Marketing status	A discontinued reference product may affect sourcing and regulatory planning
Strength and dosage form	Each strength and dosage form must be assessed separately
Exclusivity	No meaningful new-molecule exclusivity remains for the legacy product
Therapeutic equivalence	The rating affects substitution and payer acceptance

The core cefuroxime axetil patent estate is no longer the principal barrier to entry. The relevant risk is product-specific: whether a current reference product, listed formulation patent, or regulatory exclusivity position applies to the intended strength and market.

When does cefuroxime axetil oral suspension lose exclusivity?

Cefuroxime axetil oral suspension has already lost its core patent and regulatory exclusivity protection in the United States. The commercial question is therefore not when exclusivity ends, but whether a manufacturer can establish an approved, reliable, and economically viable product.

What is the Paragraph IV risk?

A Paragraph IV certification is relevant only where an ANDA applicant identifies a listed patent as invalid, unenforceable, or not infringed. For a legacy cefuroxime axetil suspension, Paragraph IV exposure is likely to be limited to any later-listed formulation or method patents rather than the original cefuroxime axetil compound patent.

A Paragraph IV filing can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework if the patent holder files suit within the statutory period.[4] Where no relevant unexpired patent is listed, the applicant may use a Paragraph III certification or a certification that no patent information is listed, depending on the Orange Book record.

Which companies are challenging cefuroxime axetil oral suspension patents?

The competitive field is primarily generic and regional. Publicly visible activity around cefuroxime axetil has historically included manufacturers such as Lupin, Teva, Dr. Reddy’s Laboratories, Sandoz, Ranbaxy, and other regional suppliers across different jurisdictions. The relevant competitive question is not only whether a company has an approval, but whether it has an actively marketed product, current manufacturing capacity, and reliable supply.

No biosimilar developers are relevant because cefuroxime axetil is a chemically synthesized small molecule. Patent litigation risk is correspondingly narrower than for biologics and is concentrated in formulation, manufacturing, and regulatory exclusivity issues.

What commercial opportunities exist for cefuroxime axetil suspension?

Can a low-cost generic compete successfully?

A conventional generic can compete on price, but price-only strategies are exposed to low margins, shortages, and pharmacy substitution pressure. The stronger opportunities are differentiated operational and formulation propositions.

Opportunity	Commercial rationale	Main development barrier
Improved taste masking	Supports pediatric adherence and caregiver acceptance	Bioequivalence and release comparability
Room-temperature stability	Reduces cold-chain dependence	Long-term and accelerated stability data
Smaller reconstitution volume	Easier dispensing and administration	Dose uniformity and viscosity control
Unit-dose packaging	Reduces preparation errors	Packaging cost and supply complexity
Preservative-free product	Pediatric positioning	Microbial robustness and in-use testing
Sugar-reduced formulation	Diabetes and dental-health positioning	Taste, viscosity, and label compliance
Aspartame-free formulation	Expands use in phenylketonuria	Taste replacement and reformulation studies
Ready-to-use suspension	Convenience and rapid dispensing	Higher shipping weight and stability burden
Hospital or clinic supply	Institutional procurement and emergency use	Tender pricing and supply guarantees
Regional licensing	Access to local registrations and distribution	Quality-system and pharmacovigilance oversight

Is there an opportunity for sugar-free cefuroxime suspension?

A sugar-free formulation could address pediatric patients requiring reduced sucrose exposure and markets that prefer non-sugar oral liquids. The formulation would need to replace sucrose’s sweetness, body, and density contribution. Polyols, high-intensity sweeteners, and polymeric viscosity modifiers can be evaluated, but polyols may create gastrointestinal tolerability concerns and high-intensity sweeteners can leave a bitter or metallic aftertaste.

A sugar-free product is commercially stronger when combined with an aspartame-free claim and a validated taste profile. The claim must remain within applicable labeling and advertising rules.

Does a ready-to-use suspension have a market advantage?

A ready-to-use product removes reconstitution errors and simplifies pediatric dispensing. Its disadvantages are higher transportation cost, larger package volume, shorter stability risk once manufactured, and greater microbial-control requirements. The best use case is a hospital, urgent-care, or retail pharmacy environment where immediate administration has measurable value.

For broad retail distribution, a dry powder remains more economical. For institutional channels, ready-to-use packaging can justify a premium if it reduces preparation time and medication errors.

What manufacturing and IP barriers affect entry?

Manufacturing cefuroxime axetil suspension requires control over both drug substance and finished-product properties. Key process controls include:

• Milling or micronization of cefuroxime axetil.
• Prevention of agglomeration during blending.
• Uniform distribution of low-dose sweeteners and flavors.
• Moisture-controlled powder handling.
• Consistent reconstitution volume.
• Shake-time and redispersion performance.
• Fill-weight accuracy.
• Container-closure integrity.
• Microbial limits before and after reconstitution.

The most defensible manufacturing know-how may not be patent-protected. Suppliers can still create barriers through proprietary particle engineering, coating processes, specialized filling equipment, stability data, and validated global manufacturing sites.

How does cefuroxime axetil suspension compare with competing pediatric antibiotics?

Cefuroxime axetil competes with amoxicillin, amoxicillin/clavulanate, cefdinir, cefpodoxime, and other oral pediatric antibiotics. Its commercial position depends on local treatment guidelines, resistance patterns, dosing frequency, taste, price, and availability.

Product	Key competitive advantage	Cefuroxime suspension implication
Amoxicillin	Low cost and broad primary-care use	Cefuroxime needs clinical or supply differentiation
Amoxicillin/clavulanate	Broad coverage	Taste and gastrointestinal tolerability can favor alternatives
Cefdinir	Strong pediatric familiarity in some markets	Cefuroxime competes through price and formulation quality
Cefpodoxime	Similar oral cephalosporin positioning	Regional registration and supply determine share
Cefuroxime axetil	Established cephalosporin prodrug and multiple strengths	Strongest opportunity is reliable pediatric delivery

Cefuroxime is not a direct substitute for every first-line antibiotic. Stewardship policies and local guidelines constrain demand. The most attractive markets are those with established cephalosporin use, pediatric outpatient volume, and limited availability of well-tolerated liquid formulations.

What litigation and settlement issues affect the product?

Because the core cefuroxime axetil patents expired long ago, current litigation is more likely to involve:

• Later formulation patents.
• Manufacturing-process patents.
• Trade secrets involving particle engineering.
• Trademark or trade-dress rights.
• Product-liability claims.
• ANDA exclusivity disputes.
• Supply and licensing contracts.

Settlement agreements would be commercially relevant only if a later patent remains enforceable and covers a commercially important formulation. For a conventional cefuroxime axetil suspension, a non-infringing formulation and standard ANDA pathway are generally more important than a patent settlement.

What licensing deals support cefuroxime axetil suspension?

The original product history is associated with GlaxoSmithKline and the Ceftin brand. Current opportunities are more likely to involve regional licensing, contract manufacturing, technology transfer, or distribution agreements than licensing of an active compound patent.

A useful licensing target would provide at least one of the following:

• Approved local suspension dossiers.
• Pediatric bioequivalence or comparative-performance data.
• Proven taste-masking technology.
• Commercial-scale dry-powder manufacturing.
• Cold-chain or non-cold-chain stability data.
• Government-tender access.
• Established pharmacy distribution.

License value should be based on active registrations, current sales, manufacturing compliance, and territory-specific market access. Historical brand ownership alone has limited value after patent expiry.

How strong is the patent estate for cefuroxime axetil oral suspension?

The patent estate is weak for the active ingredient and potentially moderate for differentiated formulations.

Patent category	Estimated strategic strength
Cefuroxime axetil compound	Low; expired
Basic oral suspension composition	Low to moderate; likely crowded and historically disclosed
Taste-masking technology	Moderate if claims are narrow and difficult to design around
Room-temperature stability	Potentially moderate to strong if supported by robust claims and data
Manufacturing process	Moderate where process parameters produce unexpected stability or uniformity
Packaging system	Low to moderate unless integrated with stability performance
Method of use	Low commercial protection for routine antibiotic indications
Regulatory exclusivity	Low for the legacy product

The best protection strategy is a layered portfolio combining formulation claims, process claims, composition-of-matter improvements where available, and trade secrets for manufacturing parameters.

What generic launch scenarios exist?

Scenario 1: Conventional low-cost generic

This product uses a conventional excipient system, refrigerated post-reconstitution storage, and standard pediatric strengths. It can launch with limited development risk but faces price competition and supply-driven substitution.

Scenario 2: Improved taste and dispensing

This product preserves the basic suspension architecture while improving flavor, redispersion, and dosing convenience. It has a stronger pharmacy and caregiver proposition without requiring a major change in clinical positioning.

Scenario 3: Room-temperature-stable product

This product targets markets where refrigeration is unreliable. The commercial upside is meaningful, but the stability program, packaging, microbial-control strategy, and regulatory burden are higher.

Scenario 4: Premium pediatric platform

This product combines sugar reduction, aspartame avoidance, unit-dose packaging, and optimized flavor. It can support institutional and specialty-retail positioning, but the addressable market is narrower and formulation development is more complex.

Key Takeaways

• Cefuroxime axetil oral suspension is an off-patent small-molecule product with no biosimilar pathway.
• The original cefuroxime axetil patent estate has expired; current risk is concentrated in later formulation, process, packaging, and regulatory rights.
• The most important excipients are sucrose, xanthan gum, hypromellose, sweeteners, flavor, povidone, colloidal silicon dioxide, and stearic acid.
• Taste masking, post-reconstitution stability, viscosity, redispersion, and microbial control determine product quality.
• A room-temperature-stable suspension is the highest-value technical opportunity but carries the greatest development burden.
• Sugar-free, aspartame-free, preservative-free, and unit-dose products offer narrower but potentially higher-margin niches.
• Generic success depends more on supply reliability, pediatric acceptability, and market access than on patent exclusivity.
• The principal regulatory route is an ANDA, subject to the current reference listed drug and Orange Book record.
• Licensing opportunities are most likely to involve approved dossiers, formulation know-how, manufacturing capacity, or distribution rights.

FAQs About Cefuroxime Axetil Oral Suspension

Is cefuroxime axetil oral suspension still commercially attractive?

Yes, but primarily as a formulation and supply opportunity. Conventional price competition is intense, while differentiated pediatric products can obtain stronger positioning.

Can cefuroxime axetil suspension be made without sucrose?

Yes. Sucrose can be replaced with alternative sweeteners and bulking agents, but the developer must re-optimize taste, viscosity, density, redispersion, stability, and pediatric acceptability.

Does cefuroxime axetil oral suspension require refrigeration?

Reference labeling generally requires refrigeration after reconstitution. A room-temperature formulation would require product-specific stability and microbiological support.

What is the main bioequivalence challenge for a cefuroxime axetil suspension?

The main challenge is demonstrating equivalent drug exposure despite differences in particle size, wetting, excipient composition, reconstitution behavior, and administration with food.

Can a new taste-masking system be patented?

Potentially. Patentability depends on novelty, inventive step, claim scope, and whether the system produces a defensible technical effect such as improved stability, taste, redispersion, or bioavailability.

References

1. U.S. Food and Drug Administration. (n.d.). Ceftin (cefuroxime axetil) tablets and oral suspension prescribing information.
2. National Library of Medicine. (n.d.). Cefuroxime axetil oral suspension: DailyMed labeling.
3. United States Patent and Trademark Office. (1985). U.S. Patent No. 4,562,181: Cefuroxime axetil.
4. U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.